New hope for Hard-to-Treat pancreatic cancer: experimental combo aims to shrink tumors before surgery
NCT ID NCT07488884
First seen Apr 05, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This early-phase trial tests a new mix of drugs (nogapendekin alfa inbakicept, sotevtamab, zabadinostat, plus standard chemo) in 30 people with pancreatic cancer that is either borderline resectable or locally advanced. The goal is to see if the combination is safe and can shrink tumors enough to allow successful surgery, followed by more immunotherapy. The study focuses on side effects and early signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.